跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
EVRYSDI - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
EVRYSDI
Authorized
STANDARD
EVRYSDI
Hoffmann-La Roche Limited
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
558586cc995ba7a8
Company
Hoffmann-La Roche Limited
Type
Standard
Approval Details
Approval Id
558586cc995ba7a8
Drug Approval Canada Name
EVRYSDI
Product Name
EVRYSDI
Status
Marketed
Status Date
2021-05-19
Original Market Date
2021-05-19
Din
02514931
Drug Class
Human
Dosage Form
Powder For Solution
Route Of Administration
Oral
Schedule
Prescription
Ahfs
92:92.00
Atc Original
M09AX10 RISDIPLAM
Atc Name
m 09 ax 10
Aig Number
0162847001
Company Name
Hoffmann-La Roche Limited
Company Address
7070 Mississauga Road, Mississauga, Ontario, Canada, L5N 5M8
Active Ingredients
RISDIPLAM
0.75 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
558586cc995ba7a8
Type
Standard
Back to Health Canada Approvals